Although only 22% knockdown efficiency was achieved (Fig. 4D), a significantly higher sensitivity to PDP1 knockdown was observed in the FLT3-ITD-positive compared to FLT3-WT AML blasts from different patients (Fig. 4E). The gene discussed is FLT3; the disease is acute myeloid leukemia.